StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
TTALO.HE$8.01-1.34%
Fair $8.01+0.0%

TTALO.HE

Terveystalo Oyj

Healthcare / Medical Care FacilitiesHelsinki

$8.01

-0.11 (-1.34%)

Fairly Valued+0.0%Fair Value $8.01Fund rank 35/100 · Data gapFallback financials|
SA 44/C
F-Score: 7/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 24% · confianza 25%

FCF escenarios

weak_data · normalized FCF $155.4M · quality 70.7/100

Data gap 35/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 78/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

44/100

C

Piotroski

7/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · TTALO.HELocal privado en este navegador · Terveystalo Oyj
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$1.0B

P/E

13.1x

↓

EV/EBITDA

6.5x

↓

ROE

15.9%

↑

Gross Margin

60.1%

↑

Debt/Equity

0.99

↑
52-Week Range$8
$7$12

TradingView lightweight chart

TTALO.HE price, volumen y niveles de valoración

Último $8.090Periodo -19.1%
Fair value: $8.010

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+0.5%

FCF CAGR

+23.9%

FCF margin

12.2%

FCF / Net income

1.68x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $1.28B · net income $92.6M · FCF $155.4M

2022-FY → 2025-FY

Gross margin

60.1%+1.9% pts

Operating margin

11.0%+5.8% pts

Net margin

7.2%+5.3% pts

FCF margin

12.2%+5.7% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$1.28B$1.28B$1.34B$1.29B$1.26B
Net Income$92.6M$92.6M$71.7M$-42.2M$24.4M
EBITDA$232.7M$232.7M$217.4M$90.7M$143.7M
EPS0.730.730.57-0.330.19
Gross Margin60.1%60.1%59.0%58.3%58.2%
Operating Margin11.0%11.0%8.9%5.5%5.2%
Net Margin7.2%7.2%5.4%-3.3%1.9%
Balance Sheet
Debt/Equity0.990.991.041.231.03
Current Ratio0.540.54———
Cash Flow
Free Cash Flow$155.4M$155.4M$184.1M$116.8M$81.7M
Returns
ROE15.9%15.9%13.1%-8.2%4.1%
Valuation
P/E13.1313.1318.81—34.32
EV/EBITDA6.546.548.5717.799.71
P/B1.741.742.481.971.40
Growth & Yield
Revenue Growth-4.6%-4.6%4.2%2.2%—
EPS Growth28.1%28.1%272.7%-273.7%—
Dividend Yield7.9%7.9%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

-0.9%

fácil

EPS terminal req.

$0.71

Spread vs growth

29.0%

5Y implied EPS CAGR

3.3%

fácil

EPS terminal req.

$0.86

Spread vs growth

24.7%

10Y implied EPS CAGR

6.6%

razonable

EPS terminal req.

$1.39

Spread vs growth

21.5%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -26.0%

Total return

-26.0%

Start / end P/E

21.5x → 11.1x

EPS bridge

0.57 → 0.73

Residual

-13.6%

EPS growth+28.1%
Multiple rerating-48.4%
Dividend+7.9%
Residual / FX / buybacks / cross-term-13.6%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.